Effects of Three Months of Low Molecular Weight Heparin (dalteparin) Treatment After Bypass Surgery for Lower Limb Ischemia—A Randomised Placebo-controlled Double Blind Multicentre Trial  by Jivegård, L. et al.
Presented at
*Correspondi
University H
Sweden.
E-mail address
1078–5884/00Effects of Three Months of Low Molecular Weight Heparin
(dalteparin) Treatment After Bypass Surgery for Lower Limb
Ischemia—A Randomised Placebo-controlled Double Blind
Multicentre Trial
L. Jivega˚rd,1* C. Drott,2 J. Gelin,1 O. Groth,3 M. Hensa¨ter,1 N. Jensen,4 G. Johansson,5
P. Konrad,6 B. Lindberg,7 A. Lindhagen,8 B. Lundqvist,9 A. Oden,10 L. Smith,11
B. Stenberg,12 E. Thornell,13 U. Wingren1 and P. O¨rtenwall11Sahlgrenska Universitetssjukhuset Go¨teborg, Go¨teborg, 2So¨dra A¨lvsborgs Sjukhus, Bora˚s, 3Centrallasarettet,
Uddevalla, 4Varbergs Lasarett, Varberg, 5Capio´ St Go¨rans Sjukhus Stockholm, Stockholm, 6So¨dersjukhuset,
Stockholm, 7Lasarettet Kunga¨lv, 8Skaraborgs Sjukhus, Sko¨vde, 9Centrallasarettet, Karlstad, 10Romelanda,
11Centrallasarettet, Halmstad, 12Universitetssjukhuset, O¨rebro, and 13Norra A¨lvsborgs Lasarett, Va¨nersborg,
SwedenObjectives. To test the hypothesis that long-term postoperative dalteparin (Fragminw, Pharmacia Corp) treatment
improves primary patency of peripheral arterial bypass grafts (PABG) in lower limb ischemia patients on acetylsalicylic acid
(ASA) treatment.
Design. Prospective randomised double blind multicenter study.
Materials and methods. Using a computer algorithm 284 patients with lower limb ischemia, most with pre-operative
ischemic ulceration or partial gangrene, from 12 hospitals were randomised, after PABG, to 5000 IU dalteparin or placebo
injections once daily for 3 months. All patients received 75 mg of ASA daily for 12 months. Graft patency was assessed at 1,
3 and 12 months.
Results. At 1 year, 42 patients had died or were lost to follow-up. Compliance with the injection schedule was 80%. Primary
patency rate, in the dalteparin versus the control group, respectively, was 83 versus 80% (n.s.) at 3 months and 59% for both
groups at 12 months. Major complication rates and cardiovascular morbidity were not different between the two groups.
Conclusions. In patients on ASA treatment, long-term postoperative dalteparin treatment did not improve patency after
peripheral artery bypass grafting. Therefore, low molecular weight heparin treatment cannot be recommended for routine use
after bypass surgery for critical lower limb ischemia.Keywords: Limb ischemia; Bypass; Graft; Patency; Low molecular weight heparin.Introduction
Critical limb ischemia (CLI) is usually caused by
peripheral atherosclerotic disease (PAD) mainly below
the renal arteries.1 In the long run a majority of CLI
patients, if untreated, will develop ischemic ulcera-
tions and gangrene provided the patient survives long
enough.1 Most patients with CLI can be successfully
treated, at least in the short-term, by peripheral arterialthe ESVS meeting in Istanbul 2002.
ng author. Lennart Jivega˚rd, PhD, MD, Sahlgrenska
ospital, Smo¨rslottsgatan 6, SE-416 65 Go¨teborg,
: lennart.jivegard@vgregion.se
0190 + 09 $35.00/0 q 2004 Elsevier Ltd. All rights resersurgery or endovascular procedures.2 In Sweden, the
majority of such patients with symptoms due to PAD
below the inguinal ligament will have a peripheral
arterial bypass graft (PABG) rather than an endovas-
cular procedure (Swedvasc 2003, unpublished obser-
vation). Although patency rates of PABG at 30 days
often is reported to be in the range of 95%, many series
report that within a year 30–40% of such grafts will be
occluded.3 Graft occlusions usually result from pro-
gression of the underlying PAD, and/or by intimal
hyperplasia (IH) either in graft-artery anastomoses, or
in the body of vein grafts.4 These lesions are believed
to involve proliferation of smooth muscle cells (SMC)
in the arterial wall in response to vascular injury.5
Heparin inhibits SMC proliferation after experimentalEur J Vasc Endovasc Surg 29, 190–198 (2005)
doi:10.1016/j.ejvs.2004.11.011, available online at http://www.sciencedirect.com onved.
Low Molecular Weight Heparin and Bypass 191arterial injury.6 Also low molecular weight heparins
(LMWH) have been reported to inhibit SMC prolifer-
ation in the experimental situation, and LMWH are
known to give a more predictable anticoagulation
response than heparin.7,8 Furthermore, the clinical
usefulness of LMWH is greater than for heparin due to
better bioavailability, the possibility of once daily
administration and the effect of LMWH to lower
plasma viscosity.9
A large number of studies have reported the
safety and efficacy of LMWH for prevention of
deep vein thrombosis (DVT) after surgery and for
treatment of DVT in outpatient settings.10,11 More
recent data suggest that LMWH also may have a
role in other vascular beds, e.g. the coronary
arteries.12 Despite the use of LMWH for DVT
prophylaxis/treatment and in acute coronary syn-
dromes, their possible role in vascular surgery
remains unclear. Edmondson and coworkers stu-
died patency at 1 year in 201 patients undergoing
femoropopliteal bypass due to CLI or intermittent
claudication and treated with long-term LMWH
(dalteparin) or acetylsalicylic acid (ASA) and
dipyridamole.13 Subgroup analysis of the 93 CLI
patients in their randomised but unblinded study
showed much higher patency at 1 year in the
dalteparin than in the control group (90 versus
48%). The implications of this study are not clear.14
If such findings are reproducible, the widespread
use of long-term LMWH treatment after peripheral
artery bypass grafting (PABG) for CLI would be
warranted.
In the present randomised double blind study we
investigated the effects of long-term treatment with
LMWH (dalteparin) injections in patients undergoing
PABG for lower limb ischemia in a large placebo-
controlled study in patients treated with low-dose
ASA.MethodsSetting
This multicentre, randomised, double blind trial was
conducted in 12 vascular surgical centres in western
Sweden and Stockholm. The study was conducted
according to the Guidelines for Good Clinical Practice
for research and the Declaration of Helsinki. It was
approved by the Ethical Committee of the Sahlgrenska
Universitetssjukhuset for the western Sweden area,
and in the Karolinska Institute for the Stockholm
Hospitals.Objectives
The primary objective was to evaluate the primary
graft patency (patent graft without any further
ipsilateral arterial intervention) 3 and 12 months
after PABG surgery in patients receiving 3 months of
treatment with the study drug, subcutaneous injection
of dalteparin (Fragminw), as compared to placebo
injections. Patients were included after having under-
gone bypass surgery for lower limb ischemia, e.g.
axillofemoral, femorofemoral, femoropopliteal, femor-
ocrural, femoropedal, axillopopliteal, iliacopopliteal,
popliteopedal, popliteopopliteal, tibiotibial, and simi-
lar bypass operations, or revisions thereof within 3
days from the primary bypass procedure (full
inclusion criteria are listed in Table 1). Upon inclusion,
before the PABG, the investigator gave information
about the study and received a signed informed
consent from the patient. Patients undergoing aortoi-
liac or aortofemoral bypass were excluded (Table 1).
Secondary objectives were to evaluate:1. healing of ischemic foot ulcerations, and the degree
of ischemic rest pain in the operated leg,2. patient acceptability of self injections as treatment
after PABG for lower limb ischemia,3. graft patency, and incidence of failing graft at 3 and
12 months in patients with a patent graft at 1 month,
and at 4–7 days after the operation, respectively,4. incidence within 12 months of bypass of myocardial
infarction, transient ischemic attacks (TIA),
unstable angina, minor and major stroke, gangrene,
re-operations (including endovascular procedures),
amputation of the ipsilateral or contralateral leg
and other bypass procedures,5. deaths within 12 months.
Included in the third secondary objective was a
comparison of the two groups with respect to the time
to the first event/and the number of events of graft
occlusion, revision for failing graft, and reoperations
including endovascular procedures.Study design
The study was multicentre, placebo controlled, ran-
domised, double blind with parallel groups. After
PABG surgery, but before randomisation, patients
once daily received 5000 IU of subcutaneous dalte-
parin. All patients underwent assessment of medical
history including concomitant medication and smok-
ing status. The physical examination included assess-
ment of the degree of ipsilateral ischemic pain,Eur J Vasc Endovasc Surg Vol 29, February 2005
Table 1. Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Lower limb ischemia due to PAD, w/wo diabetes, and with
symptoms being present for more than 2 weeks
Patient needing permanent oral anticoagulant treatment
With current symptoms including one or more of the symptoms
rest pain, ischemic ulceration, partial gangrene
Known allergy and/or definite contraindication to acetylsalicylic
acid, and/or LMWH
Operated with a PABG for lower limb ischemia Previous treatment under this protocol
w/wo a revision procedure within 1–3 days of a PABG#, but
before start of study treatment, and
Woman of childbearing potential unless taking adequate contra-
ception
Proven patency of the graft within!1 h before randomisation Patient participating in another clinical pharmaceutical study,
where another drug is under investigation
Adult of either sex,O39 years old Surgery with a known risk of increased bleeding postoperatively,
as judged by the investigator, e.g. involving the eye, ear or central
nervous system, within 3 months
Expected to surviveO1 year, and Hemorrhagic stroke within 6 months
Giving written informed consent Hemorrhagic diathesis, e.g. thrombocyto-penia (!100!109/l) or
hemophilia
Prothrombin time (PT)!50% due to hepatic disease
Renal failure (serum creatinineO260 mmol/L)
O2 revisions of the PABG after the primary operation and before
randomisation
#, peripheral arterial bypass graft
L. Jivega˚rd et al.192ischemic ulcerations and gangrene, and bilateral ankle
pressure (AP) measurements. A 12 lead ECG and
laboratory tests including haemoglobin, leukocyte and
platelet count, s-ASAT and s-ALAT, serum electrolyte
status including serum creatinine and prothrombin
level were taken.
Study drug treatment was started after the ran-
domisation, which took place 2–4 (if there was a
holiday during the weekdays, a minimum of one and a
maximum of 5 days were allowed) days after the
bypass procedure, depending on which weekday the
patient underwent the operation. Randomisation was
performed 2 days after surgery for patients operated
upon from Monday until Wednesday, after 4 days for
those operated upon on a Thursday and after 3 days
for those operated upon on a Friday.
The treatment group received dalteparin 5000 IU by
a subcutaneous injection of 0.2 mL once daily for 3
months. The control group received subcutaneous
0.2 mL placebo injection once daily for 3 months. All
patients were given 75 mg of ASA (Trombylw) orally
once daily for the 12 months follow-up period starting
no later than the same day as the first study injection.
Dalteparin sodium was supplied in pre-filled,
single-dose syringes for subcutaneous injection, each
containing 5000 anti-FXa IU/0.2 mL. Placebo syringes
contained 0,2 ml 0,9% sodium chloride and looked
identical to those containing the study medication. The
blinding procedure was ensured since the study drug
and placebo syringes were identical in appearance and
since neither the investigator/study team, nor the
patient or the monitor were before the study was
finished aware of which treatment the patient
received.Eur J Vasc Endovasc Surg Vol 29, February 2005Each patient received one box containing 40
syringes with study medication A or B by the time of
randomisation. While the patient remained in the
hospital, the investigator stored the patient’s study
drug. After discharge from the hospital the study
medication was stored in the patient’s home. Approxi-
mately 30 days after randomisation, at the first follow-
up visit, the patient received two new boxes with the
study medication, altogether containing 70 syringes.
Drug compliance during the first three study
months was assessed in a patient diary. The diary
contained data for the amount of administered
injections and the intake of ASA over a 3 months
period. The patient returned unused syringes to the
local pharmacy, where the unused syringes were
counted. After the third study month, the patient’s
intake of ASA for the remaining 9 months of the study
was reported by the patient and evaluated in connec-
tion with the follow-up visits. Good compliance for the
injections during the first 15 days was defined as at
least 12 out of 15 injections taken, and for the last 75
days at least 65 out of 75 injections taken, and not
missing injections for more than three consecutive
days. Good compliance for ASA was defined as the
patient regularly taking ASA, as reported in the
patient diary.Randomisation
In order to ensure a correct balance between the two
groups, patients were randomised using a computer
algorithm method, taking into account 17 different
parameters believed to be of potential relevance for the
patency of PABG. Data included in the randomisation
Table 2. Data included in the computer algorithm
Hospital Weekday for operation
Age Sex
Smoking last week Diabetes
Malignant disease Detsky cardiac risk index*
Preoperative ischemic rest pain (none, moderate, severe) Preoperative ischemic ulceration (none, one!3 cm, oneO3 cm or several)
Preoperative gangrene (no, yes) Ankle pressure (mmHg)
Bypass procedure Graft material (e.g. vein, PTFE)
Revision of bypass performed before randomisation No of fully patent crural arteries (from zero to three)
Surgeon’s estimation of the risk for graft occlusion within
12 months (low, medium, high)
* Ref. [15].
Low Molecular Weight Heparin and Bypass 193procedure are shown in Table 2. The surgeon
estimated the risk for graft occlusion within 12 months
as low, medium or high based on his/her own opinion,
after having performed PABG, taking into account all
available information including intra-operative
findings.
Randomisation was performed by one of two
registered nurses at the Vascular Laboratory in the
Sahlgrenska University Hospital’s Vascular Surgery
Unit. Each centre submitted a fax to the randomisation
centre, including the clinical data, and within 60 min a
reply fax was sent to the study site stating the patient
number and the clinical trial number for the patient.
Simultaneously, a second fax was sent to the hospital
pharmacy at the study site giving all details of the
patient and information on whether the patient should
receive treatment A or B. These faxes were not
available to the patient, monitor, investigator or
study team at any of the study sites. At the end of
the study when the code was broken, the signed
randomisation papers, which had been faxed to each
study centre, and the local pharmacy treatment list
were collected by the monitor together with the
checklist. The treatment code was not broken until
clean file was declared and the statistical analysis had
been performed, i.e. when all data had been entered,
checked, and the data-base was protected against
changes.Criteria for patency and assessment of ulcerations and
gangrene
Patency was assessed by standard clinical means,
including the use of a handheld Doppler, although
duplex examination was used routinely in some
centres. At 12 months a duplex examination of the
graft, or angiography, was mandatory to establish
graft patency.
A graft was considered patent if at least one of the
following criteria were met:1. Arterial pulsation palpable in one or more arteries
distal to the graft.2. Pulses palpable in the graft and arterial blood flow
(Doppler) present in the graft. Not valid for in situ
bypass.3. Arterial blood flow (Doppler) demonstrated in the
graft and post-operative ABIO0.15 higher than pre-
operative ABI.4. Distal blood flow (Doppler signal) that disappears
or decreases significantly upon proximal com-
pression of the graft, or ischemic pain and ulcera-
tions completely relieved.5. Postoperative ABIO0.20, and/or toe pressureO
20 mmHg higher than preoperatively.6. Flow demonstrated by color Doppler/duplex
and/or arteriography.7. Intra-operative findings, i.e. revision/amputation,
or suggested by an autopsy. Not valid for follow up
visits, but for patients withdrawn, lost to follow-up
or dead.8. Good skin color and better warmness of the foot,
compared to pre-operatively and compared to
contralateral foot. This criterion was used on
postoperative days 1–7 only.
If patency during follow-up was not clearly
documented at least by one of 1–5 above and it was
not clear whether the graft was occluded, a duplex
and/or an arteriography and/or a surgical procedure
was mandatory to define the patency status of the
graft. Patency also was assessed if an amputation/re-
vision involving the graft became necessary. The
presence of graft occlusion was, whenever possible,
studied in connection with autopsies in patients that
died during the follow-up period.
Severity (improved, unchanged or worsened) of
ischemic ulceration and partial gangrene was made
subjectively, by the responsible surgeon, during the
patient’s visits at the outpatient clinic. Formal
measurement of the size of ischemic ulcers and partial
gangrene was not mandatory.Eur J Vasc Endovasc Surg Vol 29, February 2005
 Fig. 1. Flow diagram of randomised patients. Explanations; *,
one patient had occluded bypass graft by the time of
randomisation and was, therefore, excluded (protocol viola-
tion); #, two patients did not continue in any form after
randomisation and were, therefore, excluded.
L. Jivega˚rd et al.194Hypothesis and determination of sample size
Graft patency, 1 year after PABG for severe limb
ischemia, was estimated to be 60% in the placeboC
ASA group, based on unpublished data from the
Swedvasc. Based on the results in the study by
Edmondson and coworkers,13 we based sample size
calculations on the hypothesis that the patency rate
would be 78% in the dalteparinCASA group. Due to
the serious nature of concomitant diseases, we
assumed that only 65–75% of the patients would
have graft follow up at 1 year. With 75% of the patients
having grafts evaluated at 1 year, with alphaZ0.05 and
betaZ80% and using two-sided tests, 280 patients
needed to be randomised. An interim analysis to
assess safety was conducted after 160 patients had
been randomised and indicated that over 80% patients
survived to have grafts evaluated at 1 year.Table 3. Clinical data at randomisation
Variable Dalteparin (nZ141) Placebo (nZ140)
Reoperation before
randomisation
7% (11) 6% (8)
Female sex 45% (63) 45% (63)
Present smoker 31% (44) 30% (42)
Malignancy 2% (3) 1% (2)
Ischemic ulcer 58% (82) 57% (80)
Partial gangrene 27% (38) 28% (39)
Diabetes 37% (52) 36% (50)
Age (SD) 73 (9) 74 (9)
Ankle pressure* (SD) 67 (56) 60 (37)
Detsky cardiac risk
index (SD)15
1.1 (0.5) 1.1 (0.3)
The percentage of the presence of each variable is given, and the
number of patients within parenthesis. There are no significant
differences between the two groups.
* Includes all patients and values, also diabetics with high ankle
pressures.Calculation of patency, and statistical methods
In the present study, patency was investigated at pre-
specified points of time (1, 3 and 12 months). In order
to facilitate comparisons with studies where patency is
spontaneously reported and presented by use of
Kaplan–Meier curves the survival functions were
calculated. The calculations were performed on the
assumption that the hazard functions were piecewise
constant, changing after 1 and 3 months. The
probabilities of graft patency in the two treatment
groups at 3 and 12 months, respectively, were
compared by Fisher’s exact test. The same test was
also used for comparison of the acceptability of
treatments. For the time to first occlusion or failing
graft, the log rank test was applied. The latter test was
applied for comparisons with respect to a set of
secondary end-points, which were registered as events
with a date. For other variables such as ischemic pain,
healing of ischemic ulcers Fisher’s permutation test
was used.16 In order to assess variables of importance
for graft patency, besides treatment with dalteparin,
logistic regression analyses were performed. The
possible effect of the duration (1–5 days) of the initial
postoperative dalteparin medication was assessed by
introducing an interaction term in the logistic model
between the duration of this initial treatment in
patients randomised to placebo. Confidence intervals
for the difference between the patency probabilities
were calculated. All tests were two-sided.Eur J Vasc Endovasc Surg Vol 29, February 2005Results
Altogether 284 patients (46% of all patients operated
upon with the mentioned peripheral arterial bypass
procedures for severe lower limb ischemia during the
inclusion period in the participating centres) were
randomised (Fig. 1). Two patients were withdrawn
early after randomisation. One further patient with an
occluded bypass by the time of randomisation also
was excluded, leaving 281 patients for final analysis:
141 in the dalteparin and 140 in the control group.
All demographic and basal clinical data for the
included patients were similar in the two groups
(Table 3). The risk for occlusion of the bypass as
estimated by the vascular surgeon after the PABG
operation was judged as low, average and high in 26,
86 and 29 dalteparin patients, respectively. The
corresponding numbers in the placebo group were
26, 85 and 29, respectively. Thirty-two patients died
during the 12 months follow-up period.
Compliance for the study injections was not
different between the two groups during early
Table 4. Twelve months patency (primary, and primary assisted) for different types of bypass and graft materials
Type of PABG Vein (V) or synthetic
(S) graft
Occluded at 12 months Patent at 12 months Primary patency rate
Axillo- or femorofemoral – 9 30 0.77
Fem-pop AK S 11 22 0.67
Fem-pop AK V 6 14 0.70
Fem-pop BK S 14 18 0.56
Fem-pop BK V 14 38 0.73
Fem-tib or -ped S 6 7 0.54
Fem-tib or -ped V 22 35 0.61
Low Molecular Weight Heparin and Bypass 195follow-up. For the first 14 days, 120/141 (85%) patients
on dalteparin showed similar, good compliance as
compared to 128/140 (91%) patients assigned to
placebo. Compliance for the injections was lower in
the dalteparin group during follow-up from day 15
and until 3 months. For this latter period 99/141 (70%)
dalteparin and 115/140 (82%) placebo patients
showed good compliance (pZ0.0269, Fisher’s exact
test). Patency was unrelated to good compliance for
both groups. Good compliance for the ASA treatment
was observed for 107/141 (76%) dalteparin and
102/140 (73%) placebo patients.
Patency at 12 months was highest for proximal
procedures (axillofemoral and femoro-femoral grafts)
and, as expected, lowest for femorotibial and femor-
opedal procedures with synthetic graft (Table 4).
Although primary patency was slightly higher in the
dalteparin (83%) versus the control group (80%) at 3
months (Fig. 2), this difference was far from significant
(pZ0.396). At 12 months, patency was identical (59%)
in the two groups. Early mortality was low, and theFig. 2. Primary patency in the dalteparin and control groups du
the two groups.deaths in each group at 1, 3 and 12 months are given in
Table 5.
Patients who had a patent (primary or primary
assisted) PABG at 12 months were compared with
those who did not (Table 5). Only the surgeon’s
estimation of the risk for occlusion, as registered after
the PABG procedure, was significantly related to graft
patency (pZ0.032) (Table 6). Age and the Detsky
cardiac risk index were close to significance (0.05!p!
0.10). None of the other randomisation variables was
related to graft patency at 12 months. Patency in the
placebo group was not associated with the duration
(1–5 days) of initial dalteparin treatment.
Change in ischemic ulceration and/or partial
gangrene was not different between the two groups
at either 3 or 12 months. In patients with diabetes
23/70 (77%) in the dalteparin and 25/32 (78%) in the
placebo group showed improved status at 12 months.
In patients without diabetes 29/45 (64%) dalteparin
patients showed improved status as compared to
27/59 (46%) placebo group patients (pZ0.0893).ring follow up. There was no significant difference between
Eur J Vasc Endovasc Surg Vol 29, February 2005
Table 5. The number of patients in the different categories at 3 and 12 months
Dalteparin at 3 months Placebo at 3 months Dalteparin at 12 months Placebo at 12 months
Primary patency 110 107 71 75
Primary assisted patency 4 2 11 7
Not patent* 14 21 26 30
Ipsilateral amputation 3 3 7 9
Dead 5 3 17 15
Missing value 5 4 9 4
* Alive and without ipsilateral amputation.
L. Jivega˚rd et al.196The amount of gangrene at 12 months, assessed as
none, less than forefoot or more than forefoot, was not
different between the two groups. In the dalteparin
group, 32/34 (94%) patients with diabetes and 65/67
(97%) patients without diabetes had no gangrenous
tissue at 12 months. The corresponding figures in the
placebo group were 31/34 (91%) and 71/72 (99%)
patients, respectively. Similarly there were no differ-
ences in the number of patients with ischemic
ulceration at 12 months. In the dalteparin group
28/35 (80%) with diabetes and 56/67 (84%) without
diabetes had no ischemic ulceration at 12 months. The
corresponding figures in the placebo group were
27/34 (79%) with diabetes and 70/73 (96%) of those
without diabetes.
Adverse events were common in both groups, but
there was no difference between the two groups (Table
7). Overall, there were 20 bleeding complications in the
dalteparin versus 17 in the placebo group. Most
reported bleeding complications were not serious,
and no treatment was needed.Table 6. Basal clinical data in patients with primary or primary
assisted patency, or not at 12 months
Variable Patency or primary assisted
patency at 12 months
Yes (nZ164) No (nZ82)
Ankle pressure, mean (SD) 65.0 (48.7) 64.8 (49.8)
Age, mean (SD) 73.9 (8.1) 72.2 (9.4)
Smoker % 30 32
Malignancy % 1 2
Ischemic ulceration % 52 62
Detsky cardiac risk index,
mean (SD)
1.07 (0.27) 1.17 (0.56)
Revision of bypass % 4 11
Highest risk for occlusion %* 14 26†
Sex % female 48 45
Diabetes % 34 34
Gangrene % 21 37
* The risk for occlusion denotes the surgeon’s opinion, as recorded
after PABG surgery, of the risk for occlusion of the bypass within 1
year.
† p!0.05.
Eur J Vasc Endovasc Surg Vol 29, February 2005Discussion
In this randomised double blind study after peripheral
arterial bypass graft surgery in patients on 75 mg of
ASA daily, we observed no difference in graft patency
at 3 or 12 months between patients receiving 5000 IU
of dalteparin daily for 3 months after bypass surgery
versus those receiving placebo injections. Active
treatment with dalteparin did not improve the
incidence of failing graft, amputation or other cardi-
ovascular complications during 12 months of follow-
up. Similarly there was no difference in either the fate
or extent of ischemic foot ulceration and/or gangrene
during 12 months of follow-up. Furthermore, there
was no difference, between the groups, in the extent of
gangrene or ischemic ulceration at 12 months.
Early mortality was low and similar in the two
groups. Mortality within 12 months was much lower
than expected from a comparison with all patients
undergoing similar operations in Sweden reported to
the Swedish In-patient Registry. Our patients were
selected for this study on the basis of an expected 12
months survival, assessed subjectively by the respon-
sible surgeon. Therefore, patients with advancedTable 7. Number of adverse events in the two groups
Adverse event Dalteparin Placebo Significance
Myocardial infarction 8 11 Ns
Unstable angina 2 2 Ns
Minor stroke# 3 2 Ns
Major stroke# 4 1 Ns
Transient ischemic
attack#
2 0 Ns
All cerebrovascular (#) 9 3 Ns (pZ0.1407)
Gangrene 5 2 Ns
Reoperations
(including EVP)
30 27 Ns
Ipsilateral amputation 13 17 Ns
Contralateral
amputation
5 6 Ns
Other bypass surgery 13 6 Ns
#, all cerebrovascular events is the sum of minor and major strokes
and transient ischemic attacks.
Low Molecular Weight Heparin and Bypass 197malignant disease were excluded, as were patients a
recent stroke or with renal failure. All trial patients
were given low dose ASA treatment, which is known
to improve survival in patients having undergone
vascular surgery.17 Possibly not all patients under-
going PABG in Sweden are given ASA after the bypass
surgery. All patients in the present study were
followed closely at least three times during the
postoperative 12 months, and follow-up visits
included recent medical history and a comprehensive
medical status. Therefore, the better survival observed
in the trial population as compared to all similar
patients in Sweden may be due both to selection of
patients at lower risk and to better treatment and
follow-up.
Previous studies of LMWH in peripheral vascular
patients have suggested that LMWH is as safe and at
least as effective as unfractionated heparin in the
prevention of DVT after vascular surgical pro-
cedures.18 In a retrospective study in which LMWH
was compared to unfractionated heparin for post-
operative anticoagulation after vascular surgery it was
suggested that LMWH was safe and effective for
postoperative anticoagulation and could reduce the
average postoperative length of stay.19 However, due
to the retrospective nature of the study, the authors
concluded that further data of prospective nature were
needed before safe conclusions could be drawn
regarding the efficacy and safety of postoperative
anticoagulation with LMWH.
The effect of LMWH, unfractionated heparin and
dextran 40 on early graft patency has been studied
previously. A randomised trial showed that
patency, 3 months after femorodistal bypass sur-
gery, was not different between patients receiving
the LMWH enoxaparin and patients receiving
dextran during the peri-operative period.20 Patency
at 3 months was of the same order of magnitude
as that observed in the present study. In another
open randomised multi-centre study of 201 patients
undergoing femoro-distal bypass surgery patients
were treated with subcutaneous LMWH or unfrac-
tionated heparin twice daily for 10 days.21 The
primary endpoint was graft patency on day 10
after surgery, as assessed clinically and/or by
arteriography during reintervention and/or
autopsy. Graft occlusion was more common in the
unfractionated heparin group (22 versus 8%, pZ
0.009). Safety was not different and no differences
were detected in other major complications. In a
randomised study published in 1998, dextran 40
did not increase early (30 days) patency after
autogenous infrainguinal bypass.22
A review published in 1999 of published clinicaltrials of adjuvant medical therapy in conjunction with
infrainguinal bypass procedures demonstrated that
only ASA in prosthetic grafts and ticlopidine in vein
grafts have been shown to improve patency.23 In the
ticlopidine study there was no significant difference
between ticlopidine and placebo regarding overall
mortality or major ischemic events.24 A large meta-
analysis of randomised trials demonstrated that anti-
platelet therapy reduced by 23% serious vascular
events (death, myocardial infarction and stroke)
among patients having undergone peripheral bypass
grafting.17 Comment was made in another review
published in 1999 that the evidence for antiplatelet
therapy and oral anticoagulants reducing the risk of
graft occlusion effects is based on a small number of
trials only.25 In the Dutch Bypass Oral Anticoagulants
or Aspirine Study published by the same authors a
year later, oral anticoagulation was shown to be
superior for prevention of infrainguinal vein graft
occlusion and for lowering the rate of ischemic events,
with optimum anticoagulation with an INR in
between 3.0 and 4.0.26,27In contrast, ASA appeared
better for the prevention of prosthetic graft occlusion,
and was associated with fewer bleeding episodes.26
In a recent study, the ischemia induced by femor-
opopliteal bypass graft occlusion was observed to be
worse with PTFE than with vein grafts, and the
combined treatment with oral anticoagulants and
aspirin was found to lessen the severity of the acute
ischemia after occlusion of PTFE grafts as compared
with aspirin treatment alone.28 Such an effect was not
observed in femoropopliteal vein grafts, and occlusion
of such grafts was rarely accompanied by severe
ischemia.
We based our hypothesis for a beneficial effect of
dalteparin on the observations of Edmondson and
coworkers,13 but our study differs markedly. We
undertook a double blind trial and did not include
patients with intermittent claudication. In the Edmon-
son study, the techniques/criteria used to define graft
patency was not described, both patients and investi-
gators were aware of the treatment allocation and only
the control group received ASA treatment (in addition
to dipyridamole). Our study design permits more
robust conclusions to be drawn.
In summary, the results of this study do not support
the hypothesis that, in patients with severe lower limb
ischemia, the patency of peripheral arterial bypass
grafts is improved by the use of long-term post-
operative LMWH treatment. Therefore, we believe
routine long-term LMWH treatment after peripheral
arterial bypass graft surgery for lower limb ischemia is
not justified.Eur J Vasc Endovasc Surg Vol 29, February 2005
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